Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations

Assessment of measurable residual disease (often referred to as “minimal residual disease”) has emerged as a highly sensitive indicator of disease burden during and at the end of treatment and has been correlated with time-to-event outcomes in chronic lymphocytic leukemia. Undetectable-measurable re...

Descripción completa

Detalles Bibliográficos
Autores principales: Wierda, William G., Rawstron, Andrew, Cymbalista, Florence, Badoux, Xavier, Rossi, Davide, Brown, Jennifer R., Egle, Alexander, Abello, Virginia, Cervera Ceballos, Eduardo, Herishanu, Yair, Mulligan, Stephen P., Niemann, Carsten U., Diong, Colin P., Soysal, Teoman, Suzuki, Ritsuro, Tran, Hoa T. T., Wu, Shang-Ju, Owen, Carolyn, Stilgenbauer, Stephan, Ghia, Paolo, Hillmen, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550962/
https://www.ncbi.nlm.nih.gov/pubmed/34168283
http://dx.doi.org/10.1038/s41375-021-01241-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550962/
https://www.ncbi.nlm.nih.gov/pubmed/34168283
http://dx.doi.org/10.1038/s41375-021-01241-1

Ejemplares similares